FDA Authorizes New COVID-19 Vaccine Without Clinical Data

Novavax’s shot, which targets the JN.1 variant, has been authorized.

A dose of Novavax's COVID-19 vaccine is prepared, in this file image. Joroen Jumelet/ANP/AFP via Getty Images

The U.S. Food and Drug Administration (FDA) has authorized a new COVID-19 vaccine from Novavax, giving Americans an alternative to shots from Moderna and Pfizer.

Novavax’s protein-based vaccine will be available soon after regulators granted emergency authorization to the Maryland-based company for the product.